Abstract |
We tested the hypothesis that olmesartan, an angiotensin II receptor blocker (ARB) devoid of peroxisome proliferator-activated receptor γ agonist activity, would improve whole-body insulin sensitivity in overweight and obese individuals with elevated blood pressure (BP). Sixteen individuals (8 women, 8 men; age=49.5 ± 2.9 years; body mass index=33.0 ± 1.7 kg/m2) were randomly assigned in a crossover manner to control and ARB interventions. Insulin sensitivity was determined from intravenous glucose tolerances tests before and after each 8-week intervention. BP, body weight, body fat, lipid and lipoprotein concentrations, and insulin sensitivity were similar at baseline for both treatments (all p > 0.05). Diastolic BP and triglyceride concentrations were higher (p = 0.007 and 0.042 respectively) at baseline for the ARB compared with the control intervention. Systolic (-11.7 mmHg; p = 0.008) and diastolic (-12.1 mmHg; p = 0.0001) BP decreased, however insulin sensitivity did not change (p > 0.05) following ARB treatment. Furthermore, there were no significant correlates of changes in insulin sensitivity following the ARB intervention. In summary, our findings indicate that short-term ARB treatment did not affect whole-body insulin sensitivity in overweight or obese individuals with elevated BP. Future studies are needed to clarify the effect of individual ARBs on insulin sensitivity in obesity.
|
Authors | Elaina L Marinik, Madlyn I Frisard, Matthew W Hulver, Brenda M Davy, Jose M Rivero, Jyoti S Savla, Kevin P Davy |
Journal | Therapeutic advances in cardiovascular disease
(Ther Adv Cardiovasc Dis)
Vol. 7
Issue 1
Pg. 11-20
(Feb 2013)
ISSN: 1753-9455 [Electronic] England |
PMID | 23328189
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Angiotensin Receptor Antagonists
- Imidazoles
- Tetrazoles
- olmesartan
|
Topics |
- Angiotensin Receptor Antagonists
(therapeutic use)
- Biopsy
- Cross-Over Studies
- Female
- Glucose Tolerance Test
- Humans
- Hypertension
(complications, drug therapy, metabolism)
- Imidazoles
(therapeutic use)
- Insulin Resistance
(physiology)
- Male
- Middle Aged
- Muscle, Skeletal
(metabolism)
- Obesity
(complications, metabolism)
- Overweight
(complications, metabolism)
- Renin-Angiotensin System
(drug effects, physiology)
- Tetrazoles
(therapeutic use)
- Treatment Outcome
|